Revenues soared to EGP 1.163 billion in nine months to September 30th from EGP 630.477 million the year before.
Pfizer announced its success in providing the latest treatments to 7 million patients in Egypt, and its goal to reach 7.6 million end of year.
The agreement is for the commercialization of multiple biosimilar candidates developed and manufactured by Alvotech.
Biontech delivered a vaccine against Corona at a record pace. In the meantime, demand for Comirnaty, still the world's top-selling drug, is flagging.
Both the government and private sector are keen on achieving sustainability, according to the manager at the Swiss multinational healthcare company.
El-Dababi made his comments during his participation in the third edition of Al-Ahram Establishment’s two-day pharmaceutical conference.
The 1st decision was issued last year within a comprehensive state plan to protect citizens from any possible repercussions of COVID-19.
“greening" operations means improving production efficiencies and boosting the company’s productivity.
BioBusiness explained that the BioVENT A Series was manufactured in the factories of the Arab Organisation for Industrialisation as the partner.
The WHO will offer recommendations based on international standards and experience that will help Egypt upgrade its system.
The organisation of the Africa Health ExCon (AHE) in Egypt is a golden opportunity for the country to become a hub for exporting pharmaceuticals.
One of the drugs, Merck, is taken orally, and four Egyptian companies have applied to manufacture it locally.
This came on the sidelines of signing a partnership agreement with Link Datacenter and Microsoft.
Egypt to train Uganda doctors, offer 20 scholarships within the framework of the depth of relations between Egypt and all African countries.
The government is continuously increasing the budget of the healthcare sector, said Minister of Finance Mohamed Maait on Saturday.
Cooperation includes research, clinical trials for serums, vaccines, and biologicals.
a new company focused on consumer health products will be established in Egypt, while GSK Egypt will continue to produce and market pharmaceuticals.
Cairo, Port Said, Ismailiya, Sinai, Aswan, Luxor, Matrouh and Qena will all be included in the program that will be implemented over 3 years.
RDIF and Minapharm will initially supply over 40 million doses per year. Production will take place in Minapharm's biotech facility in Cairo.